Metastatic Colorectal Cancer Immunotherapy with GUCY2C-Expressing Listeria monocytogenes

This objective of this project is to define the ability of a new vaccine to treat colorectal cancer in animal models. The vaccine uses attenuated Listeria monocytogenes to deliver GUCY2C, a colorectal cancer antigen to antigen-presenting cells APCs to induce GUCY2C-specific T cell responses against GUCY2C which may find and eliminate colorectal cancer. The project tests novel recombinant Listeria monocytogenes vaccines produced in our laboratory in mouse models of colorectal cancer to determine their activity, efficacy, and safety. If successful, the results of these studies could be applied to patients with metastatic colorectal cancer, a disease that is typically fatal.